Savara (NASDAQ:SVRA) Shares Gap Up Following Analyst Upgrade

Key Points

• Savara Inc. saw a significant increase in its share price after Oppenheimer raised its price target from $5.00 to $6.00, with the stock opening at $3.28, up from a previous close of $3.01.
• Several analysts have expressed positive ratings for Savara, with a consensus price target of $6.17 and the majority categorizing it as a "Moderate Buy."
• Insider transactions included Director Richard J. Hawkins purchasing 48,225 shares at an average price of $2.04, increasing his stake in the company by 71.72%.

Savara Inc. (NASDAQ:SVRA - Get Free Report) shares gapped up before the market opened on Friday after Oppenheimer raised their price target on the stock from $5.00 to $6.00. The stock had previously closed at $3.01, but opened at $3.28. Oppenheimer currently has an outperform rating on the stock. Savara shares last traded at $3.00, with a volume of 436,237 shares trading hands.

A number of other analysts have also recently issued reports on the company. HC Wainwright raised Savara from a "neutral" rating to a "buy" rating and lifted their price objective for the company from $2.00 to $5.00 in a research report on Friday, August 15th. Wells Fargo & Company reduced their price objective on Savara from $8.00 to $7.00 and set an "overweight" rating for the company in a research report on Wednesday, May 28th. Guggenheim reaffirmed a "buy" rating and issued a $8.00 price target (down previously from $9.00) on shares of Savara in a research report on Wednesday, May 28th. Finally, Evercore ISI reduced their price target on Savara from $3.00 to $2.00 and set an "in-line" rating for the company in a research report on Wednesday, May 28th. Five investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $6.17.

Insider Buying and Selling at Savara

In related news, Director Richard J. Hawkins purchased 48,225 shares of Savara stock in a transaction on Friday, June 20th. The stock was bought at an average price of $2.04 per share, with a total value of $98,379.00. Following the completion of the transaction, the director directly owned 115,466 shares of the company's stock, valued at approximately $235,550.64. This represents a 71.72% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 5.13% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Savara

Large investors have recently made changes to their positions in the business. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of Savara by 24.8% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 156,983 shares of the company's stock worth $482,000 after purchasing an additional 31,168 shares during the last quarter. Millennium Management LLC lifted its position in shares of Savara by 71.8% during the 4th quarter. Millennium Management LLC now owns 482,263 shares of the company's stock worth $1,481,000 after purchasing an additional 201,599 shares during the last quarter. Deutsche Bank AG lifted its position in shares of Savara by 6.1% during the 4th quarter. Deutsche Bank AG now owns 927,595 shares of the company's stock worth $2,848,000 after purchasing an additional 53,054 shares during the last quarter. D. E. Shaw & Co. Inc. lifted its position in shares of Savara by 314.7% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 70,560 shares of the company's stock worth $217,000 after purchasing an additional 53,547 shares during the last quarter. Finally, Farther Finance Advisors LLC lifted its position in shares of Savara by 25.3% during the 1st quarter. Farther Finance Advisors LLC now owns 32,314 shares of the company's stock worth $92,000 after purchasing an additional 6,532 shares during the last quarter. Institutional investors and hedge funds own 87.93% of the company's stock.

Savara Stock Up 1.3%

The company has a current ratio of 11.08, a quick ratio of 11.08 and a debt-to-equity ratio of 0.25. The firm has a market cap of $534.08 million, a price-to-earnings ratio of -6.18 and a beta of 0.40. The firm has a 50-day moving average of $2.44 and a two-hundred day moving average of $2.67.

Savara (NASDAQ:SVRA - Get Free Report) last posted its quarterly earnings data on Wednesday, August 13th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.02). As a group, sell-side analysts predict that Savara Inc. will post -0.45 earnings per share for the current fiscal year.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.